Section 1. Report Objective, and Methodology
- Scope of Research
- Research Methodology
- Assumptions
- Research Sources
- Primary Research
- Secondary Research
- Paid Sources
Section 2. Report Summary
- Global Market Snapshot, 2021-2030
- Executive Summary by Segments
- Market Overview, By Product Type
- Market Overview, By Marketed Brands
- Market Overview, By Distribution Channel
- Market Overview, By Region
Section 3. Key Insights
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Developments
- Leading Brands
- Price Trend Analysis
- Pipeline Analysis
- Porter’s Analysis
- Epidemiology
- Technology Insights
- Impact of COVID-19
Section 4. Global Human Recombinant Insulin Market By Product Type, Market Size, and Revenue Opportunity (USD Billion, 2022-2030)
- Global Industry Overview, By Product Type
- Market Size, US$ Bn
- Market Share Analysis, 2022 and 2030 (%)
- Market Trends and Dynamics
- Rapid-Acting Human Insulin (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Short-Acting Human Insulin (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Million))
- Intermediate-Acting Human Insulin (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Long-Acting Human Insulin (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Premixed Human Insulin (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
Section 5. Global Human Recombinant Insulin Market By Brand, Market Size, and Revenue Opportunity (USD Billion, 2022-2030)
- Global Industry Overview, By Marketed Brands
- Market Size, US$ Bn
- Market Share Analysis, 2022 and 2030 (%)
- Market Trends and Dynamics
- Humalog (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Novolog (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Apidra (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Humulin R (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Novolin R (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Humulin N (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Novolin N (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Levemir (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Lantus (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Humalog Mix (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Novolog Mix (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Others (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
Section 6. Global Human Recombinant Insulin Market By Distribution Channel, Market Size, and Revenue Opportunity (USD Billion, 2022-2030)
- Global Industry Overview, By Distribution Channel
- Market Size, US$ Bn
- Market Share Analysis, 2022 and 2030 (%)
- Market Trends and Dynamics
- Hospital Pharmacies (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Retail Pharmacies (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Online Pharmacies (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
Section 7. Global Human Recombinant Insulin Market By Region, Market Size, and Revenue Opportunity (USD Billion, 2022-2030)
- Global Industry Overview, By Distribution Channel
- Market Size, US$ Bn
- Market Share Analysis, 2022 and 2030 (%)
- Market Trends and Dynamics
- North America
- By Product Type (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Marketed Brands (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Country (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- U.S.
- Canada
- Latin America
- By Product Type (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Marketed Brands (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Country (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Brazil
- Mexico
- Rest of Latin America
- Europe
- By Product Type (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Marketed Brands (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Country (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- By Product Type (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Marketed Brands (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Country (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- China
- Japan
- South Korea
- India
- ASEAN
- Rest of APAC
- Middle East and Africa
- By Product Type (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Marketed Brands (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- By Country (Market Size and Forecast, and Y-o-Y Growth, 2022–2030, (US$ Billion))
- Saudi Arabia
- UAE
- Rest of MEA
Section 8. Company Profiles
- Novo Nordisk A/S
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
- Eli Lilly and Company
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
- Sanofi S.A.
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
- Julphar Gulf Pharmaceutical Industries
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
- Biocon Limited
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
- Bioton S.A.
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
- Gan & Lee Pharmaceuticals Ltd.
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
- Zhuhai United Laboratories Co., Ltd.
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
- Wanbang Biopharmaceuticals Co., Ltd.
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
- Dongbao Enterprise Group Co., Ltd.
- Company Overview
- Product Portfolio and Performance
- Financial Performance
- Technology Insights
- Strategic Initiatives
Frequently Asked Questions
The current market size of the Human Recombinant Insulin industry is approximately US$ 37.9 billion.
Factors such as the increasing prevalence of diabetes and advancements in insulin delivery technologies are contributing significantly to the growth of the Human Recombinant Insulin market.
Key factors hampering the growth of the Human Recombinant Insulin Market include pricing pressures and competition from biosimilar insulin products.
The leading component segment in the Human Recombinant Insulin Market is the Insulin Analog segment.
Major players operating in the Human Recombinant Insulin Market include Novo Nordisk, Eli Lilly, Biocon Ltd., and Sanofi.
The CAGR of the Human Recombinant Insulin Market is projected to be around 7.8%, with a market size expected to reach US$ 64 billion by 2030